Hematologic Malignancy
B-Cell Non-Hodgkin Lymphoma
CI-CAN-00000471Explore in graph →
Hematologic1,757 active trials43 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000471Explore in graph →
Clinical trials
6,181 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (954)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03379584 | A Safety Study of SGN-CD48A in Patients With Multiple Myeloma | terminated | Phase 1 | 14 | Seagen Inc.INDUSTRY | 1 | Sep 18, 2019 | clinicaltrials |
| NCT02092909 | Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia(8400-401) | terminated | Phase 1 / Phase 2 | 31 | Idera Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 10, 2019 | clinicaltrials |
| NCT00276159 | Study of Immune Response Modifier in the Treatment of Hematologic Malignancies | terminated | Phase 2 | 6 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 4, 2019 | clinicaltrials |
| NCT02614508 | Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | terminated | Phase 1 | 1 | Emory UniversityOTHER | 1 | Sep 3, 2019 | clinicaltrials |
| NCT02954796 | A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 | 27 | Seagen Inc.INDUSTRY | 1 | Aug 12, 2019 | clinicaltrials |
| NCT00167180 | Post Transplant Donor Lymphocyte Infusion | terminated | Phase 2 | 57 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 30, 2019 | clinicaltrials |
| NCT01875237 | Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene | terminated | Phase 1 / Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2019 | clinicaltrials |
| NCT01111188 | Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma | terminated | Phase 1 | 20 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 27, 2019 | clinicaltrials |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload | terminated | Phase 2 | 1 | City of Hope Medical CenterOTHER | 1 | Jun 18, 2019 | clinicaltrials |
| NCT02106091 | Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL | terminated | Phase 1 | 16 | Affimed GmbHINDUSTRY | 4 | Jun 18, 2019 | clinicaltrials |
| NCT01408043 | Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma | terminated | N/A | 25 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 14, 2019 | clinicaltrials |
| NCT03333746 | Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 2 | 1 | Yvonne EfeberaOTHER | 1 | May 30, 2019 | clinicaltrials |
| NCT02592876 | Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma | terminated | Phase 2 | 81 | Seagen Inc.INDUSTRY | 1 | May 17, 2019 | clinicaltrials |
| NCT02907073 | Positron Emission Tomography (PET) Imaging Studies With NIS Reporter | terminated | Phase 1 / Phase 2 | 8 | Mayo ClinicOTHER | 1 | May 17, 2019 | clinicaltrials |
| NCT02613182 | Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis(OLE) | terminated | Phase 2 | 34 | Prothena Biosciences Ltd.INDUSTRY | 1 | May 16, 2019 | clinicaltrials |
| NCT02258529 | Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma | terminated | Phase 2 | 10 | Gilead SciencesINDUSTRY | 1 | May 14, 2019 | clinicaltrials |
| NCT01927718 | Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT) | terminated | N/A | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 29, 2019 | clinicaltrials |
| NCT03558750 | Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma | terminated | Phase 1 | 6 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Apr 25, 2019 | clinicaltrials |
| NCT01287741 | A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA) | terminated | Phase 3 | 1,418 | Hoffmann-La RocheINDUSTRY | 29 | Apr 12, 2019 | clinicaltrials |
| NCT02900248 | CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice(N1) | terminated | — | 23 | CureOneOTHER | 1 | Apr 2, 2019 | clinicaltrials |
| NCT03154047 | Study in Subjects With Light Chain (AL) Amyloidosis | terminated | Phase 2 | 80 | Prothena Biosciences Ltd.INDUSTRY | 10 | Mar 26, 2019 | clinicaltrials |
| NCT01370694 | Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001) | terminated | Phase 1 | 7 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 15, 2019 | clinicaltrials |
| NCT02855359 | Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma | terminated | Phase 2 | 24 | Seagen Inc.INDUSTRY | 2 | Mar 11, 2019 | clinicaltrials |
| NCT00648739 | Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM | terminated | Phase 1 / Phase 2 | 26 | Alexion Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 5, 2019 | clinicaltrials |
| NCT00920556 | A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma | terminated | Phase 2 | 24 | Sirtris, a GSK CompanyINDUSTRY | 2 | Feb 27, 2019 | clinicaltrials |
| NCT03379493 | Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma | terminated | Phase 1 | 4 | Eureka Therapeutics Inc.INDUSTRY | 1 | Feb 4, 2019 | clinicaltrials |
| NCT02145598 | Treatment Optimization in Patients With Untreated Multiple Myeloma(GERMAIN) | terminated | Phase 2 / Phase 3 | 85 | Dr. med. Lars-Olof MueggeOTHER | 1 | Jan 16, 2019 | clinicaltrials |
| NCT03132584 | Cyclophosphamide and Alemtuzumab In Lymphoma | terminated | Phase 1 | 3 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 14, 2019 | clinicaltrials |
| NCT03218163 | MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple Myeloma | terminated | Phase 2 | 1 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 14, 2019 | clinicaltrials |
| NCT01892293 | CT Antigen TCR-Engineered T Cells for Myeloma | terminated | Phase 1 / Phase 2 | 6 | AdaptimmuneINDUSTRY | 1 | Jan 10, 2019 | clinicaltrials |
| NCT01303965 | Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM) | terminated | Phase 1 / Phase 2 | 14 | Sherif S. FaragOTHER | 1 | Jan 8, 2019 | clinicaltrials |
| NCT02008006 | BENdamustine at Elevated Dose for Relapsed Follicular Lymphoma in Intensification Therapy and Transplantation (BENEFIT)(BENEFIT) | terminated | Phase 2 | 21 | Centre Leon BerardOTHER | 1 | Jan 8, 2019 | clinicaltrials |
| NCT02454270 | A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies | terminated | Phase 1 | 59 | Janssen Research & Development, LLCINDUSTRY | 5 | Dec 20, 2018 | clinicaltrials |
| NCT01470131 | A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma | terminated | Phase 3 | 147 | AB ScienceINDUSTRY | 2 | Dec 19, 2018 | clinicaltrials |
| NCT01374217 | Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma | terminated | Phase 2 | 14 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 10, 2018 | clinicaltrials |
| NCT01203930 | A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL | terminated | Phase 2 | 105 | Gilead SciencesINDUSTRY | 1 | Nov 16, 2018 | clinicaltrials |
| NCT02376933 | Vertebral Augmentation and Radiotherapy of Collapse Spinal Metastatic Cancer | terminated | N/A | 11 | University of ArizonaOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT00790842 | Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction(PrE1003) | terminated | Phase 1 / Phase 2 | 63 | PrECOG, LLC.OTHER | 1 | Oct 24, 2018 | clinicaltrials |
| NCT01676961 | Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy | terminated | Phase 2 | 5 | NYU Langone HealthOTHER | 1 | Oct 15, 2018 | clinicaltrials |
| NCT02075021 | Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma(rev/abraxane) | terminated | Phase 1 / Phase 2 | 3 | NYU Langone HealthOTHER | 1 | Oct 15, 2018 | clinicaltrials |
| NCT01672736 | A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma | terminated | Phase 1 / Phase 2 | 19 | University Health Network, TorontoOTHER | 2 | Sep 13, 2018 | clinicaltrials |
| NCT02462525 | Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma | terminated | Phase 1 | 74 | AbbVieINDUSTRY | 4 | Sep 13, 2018 | clinicaltrials |
| NCT02489500 | Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib(VelRand) | terminated | Phase 3 | 3 | Boston Medical CenterOTHER | 1 | Sep 10, 2018 | clinicaltrials |
| NCT00918463 | A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | terminated | Phase 2 | 2 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 31, 2018 | clinicaltrials |
| NCT00847223 | Efficacy and Safety of the Farnesyl-transferase Inhibitor (Tipifarnib) in Mantle Cell Lymphoma | terminated | Phase 2 | 11 | Lymphoma Study AssociationOTHER | 0 | Aug 23, 2018 | clinicaltrials |
| NCT02030483 | Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma(PD + RD) | terminated | Phase 1 | 9 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 22, 2018 | clinicaltrials |
| NCT02702141 | A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma | terminated | Phase 1 | 44 | Seagen Inc.INDUSTRY | 1 | Aug 13, 2018 | clinicaltrials |
| NCT00012298 | Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 81 | National Cancer Institute (NCI)NIH | 1 | Aug 9, 2018 | clinicaltrials |
| NCT00124579 | S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 2 | 7 | SWOG Cancer Research NetworkNETWORK | 1 | Aug 9, 2018 | clinicaltrials |
| NCT02720510 | A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)(PANORAMA4) | terminated | Phase 2 | 6 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 24, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Sep 18, 2019source: clinicaltrials